Pimocard Plus is an advanced veterinary cardiac formulation developed for the management of congestive heart failure (CHF), atrioventricular valvular insufficiency (AVVI), and mitral valve disease (MVD) in dogs. This innovative triple-action formula combines Pimobendan, Benazepril Hydrochloride, and Co-enzyme Q10 to provide comprehensive cardiovascular support, improve cardiac efficiency, and protect vital organs affected by chronic heart disease.
Pimobendan acts as an inodilator, improving heart muscle contractility while reducing cardiac workload. Benazepril Hydrochloride, an ACE inhibitor, helps lower vascular resistance, reduce blood pressure, and slow the progression of heart disease. Co-enzyme Q10 provides powerful antioxidant support and enhances cellular energy production within cardiac tissues, contributing to long-term heart health.
Beyond cardiovascular support, Pimocard Plus offers end-organ protection by supporting healthy kidney, liver, brain, and ocular function. Its renoprotective properties make it particularly beneficial in cardiac patients suffering from concurrent chronic kidney disease (CKD). Available in multiple strengths for precise weight-based dosing, Pimocard Plus delivers effective, long-term management of canine heart disease while helping improve quality of life.
Key Benefits
- Supports management of congestive heart failure (CHF).
- Effective in atrioventricular valvular insufficiency (AVVI).
- Helps manage mitral valve disease (MVD).
- Improves cardiac contractility and pumping efficiency.
- Reduces cardiac workload and vascular resistance.
- Supports healthy blood circulation.
- Provides antioxidant protection to cardiac tissues.
- Offers kidney, liver, brain, and eye protection.
- Suitable for dogs with concurrent chronic kidney disease.
- Supports long-term cardiac health and quality of life.
Composition
Pimocard Plus 2.5 mg
- Pimobendan – 2.5 mg
- Benazepril Hydrochloride – 5 mg
- Co-enzyme Q10 – 10 mg
Indications
- Congestive Heart Failure (CHF)
- Atrioventricular Valvular Insufficiency (AVVI)
- Mitral Valve Disease (MVD)
- Dilated Cardiomyopathy (DCM)
- Cardiac Enlargement
- Chronic Heart Disease Management
- End-Organ Protection
- Chronic Kidney Disease with Cardiac Disorders
- Long-Term Cardiovascular Support
Dosage & Administration
General Dose
- Pimobendan: 0.2–0.6 mg/kg body weight daily
- Common therapeutic dose: 0.5 mg/kg body weight daily
- Administer as directed by a veterinarian, often alongside other cardiac medications.
Weight-Based Dosing Guide
| Body Weight |
Recommended Dose |
| 10 – 20 kg |
1 × 2.5 mg tablet twice daily |
| 20 – 30 kg |
1 × 5 mg tablet twice daily |
| 30 – 40 kg |
1.5 × 5 mg tablets twice daily |
| 40 – 60 kg |
2 × 5 mg tablets twice daily |
Available Variants
- Pimocard Plus 1.25 mg
- Pimocard Plus 2.5 mg
- Pimocard Plus 5 mg
Product Information
Brand: Swiss Biocare
Product Type: Veterinary Cardiac Support Tablet
Suitable For: Dogs
Use For: Congestive Heart Failure, Mitral Valve Disease & Cardiac Support
Form: Tablet
Class: Inodilator, ACE Inhibitor & Cardiac Nutraceutical Combination
